Cowen and Company’s Immunic IMUX Stock Holding History

Cowen and Company’s Portfolio IMUX Stock Details IMUX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-2,450	Closed	-$6K	–	701
2022 Q1	$6K	Buy	+2,450	New	+$284K	﹤0.01%	537

Other funds holding IMUX

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Gratus Capital Atlanta, Georgia $2.5B AUM 32.89% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Cowen and Company's IMUX Position: Q1 2024 in Review

Cowen and Company sold out of Immunic (IMUX) in Q1 2024, closing a stake of 31,706 shares — an estimated $476K sold.

Cowen and Company first reported a position in IMUX in Q4 2021 and held it in 9 quarters. The position peaked at $14.2M in Q1 2022. 59 funds tracked by Wall St. Rank hold IMUX as of Q1 2024.

Cowen and Company reported no remaining Immunic position as of Q1 2024 after selling out during the quarter.
Cowen and Company sold 31,706 Immunic shares in Q1 2024, an estimated $476K.
Cowen and Company first reported a position in Immunic in Q4 2021 and held it in 9 quarters.
Cowen and Company's Immunic position peaked at $14.2M in Q1 2022.
59 funds tracked by Wall St. Rank held Immunic as of Q1 2024.

Based on Cowen and Company's 13F filing for Q1 2024, filed 3 May 2024.